In celebration of Clinical Trials Week, Dr. Lindsay Weitzel talks to Dr. Tim Smith about how the current ongoing migraine clinical trials and how they have been impacted by the COVID-19 crisis. Will we see delays in the approval and release of some of our…
What has been accomplished at Headache on the Hill 2020? Tune in for an update on progress from Headache on the Hill Advocacy with Katie MacDonald (Executive Director of Alliance for Headache Disorders Advocacy) and Dr. Lindsay Weitzel.
Get free access to watch the 2020 Migraine World Summit The largest patient event in the world for migraine and headache disorders returns this March 18-26. The Migraine World Summit will bring together experts, including doctors and specialists, to share new treatments, research, and strategies…
Dr. Gretchen Tietjen joined Dr. Lindsay Weitzel to discuss childhood abuse and the development of migraine. Click this link to read about Dr. Tietjen’s groundbreaking research on the link between adverse childhood experiences (ACE) and the development of migraine later in life.
The Migraine World Summit is the largest patient event in the world for migraine and headache disorders. The Migraine World Summit will bring together 32 experts, including doctors and specialists, to share new treatments, research, and strategies to help you improve your migraine and chronic…
As part of its 2018 funding cycle, the National Headache Foundation has awarded a $100,000 grant to fund a nationwide study conducted by Dr. Erin Buchanan of Harrisburg University of Science and Technology and Clinvest Research. The goal of the project will be to improve…
The National Headache Foundation is proud to be participating in Headache on the Hill, an annual congressional advocacy event on February 11 and 12, 2019. Headache on the Hill participants visit the offices of approximately 130 members of Congress to raise issues on behalf of those…
The National Headache Foundation applauds the approval and release of Teva Pharmaceutical’s migraine preventive medication, Ajovy (fremenazumab), on Friday, September 14, 2018. This medication is the second in a new class of migraine preventers called CGRP monoclonal antibodies to be approved in 2018, with another…
The National Headache Foundation has begun to conduct surveys with thousands of our patient members on important topics: affordability of care; meaningful migraine relief; satisfaction with medications and treatment; etc. The results are accumulating and we are beginning to analyze some of the data. Â …
Subscribe to our Monthly e-Newsletter
Gain access to the most current migraine and headache information, prevention,
treatment, research, and news.
